Neuraxis announces FDA 510k clearance of RED for testing, evaluation

NeurAxis (NRXS) announced the US Food and Drug Administration, FDA, granted a 510(k) clearance for RED, Rectal Expulsion Device, allowing NeurAxis to commercially market the device for testing and evaluation of patients with chronic constipation due to pelvic floor dyssynergia and who are unlikely to improve with increased laxative use.